Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile

Liver Transplantation

Volumn 19, Issue 10, 2013, Pages 1142-1150

  Gotthardt, Daniel Nils ^a   Senft, Jonas ^a   Sauer, Peter ^a   Weiss, Karl Heinz ^a   Flechtenmacher, Christa ^a   Eckerle, Isabella ^b   Schaefer, Yvonne ^a   Schirmacher, Peter ^a   Stremmel, Wolfgang ^a   Schemmer, Peter ^a   Schnitzler, Paul ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ADULT; ANASTOMOSIS; ARTICLE; BILE; CHOLANGITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; INFECTION RISK; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OCCULT CYTOMEGALOVIRUS CHOLANGITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECIPIENT; VIRUS DETECTION;

ADULT; AGED; ANASTOMOSIS, SURGICAL; BILE; BIOPSY; CHOLANGITIS; CHOLESTASIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK;

EID: 84884875750     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23713     Document Type: Article

References (33)

1. Greif F, Bronsther OL, Van Thiel DH, Casavilla A, Iwatsuki S, Tzakis A, et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg 1994; 219: 40-45.
2. Verran DJ, Asfar SK, Ghent CN, Grant DR, Wall WJ,. Biliary reconstruction without T tubes or stents in liver transplantation: report of 502 consecutive cases. Liver Transpl Surg 1997; 3: 365-373.
3. O'Connor TP, Lewis WD, Jenkins RL,. Biliary tract complications after liver transplantation. Arch Surg 1995; 130: 312-317.
4. Op den Dries S, Sutton ME, Lisman T, Porte RJ,. Protection of bile ducts in liver transplantation: looking beyond ischemia. Transplantation 2011; 92: 373-379.
5. Verdonk RC, Buis CI, Porte RJ, Haagsma EB,. Biliary complications after liver transplantation: a review. Scand J Gastroenterol Suppl 2006; 243: 89-101.
6. Aberg F, Mäkisalo H, Höckerstedt K, Isoniemi H,. Infectious complications more than 1 year after liver transplantation: a 3-decade nationwide experience. Am J Transplant 2011; 11: 287-295.
7. Andrews PA, Emery VC, Newstead C,. Summary of the British Transplantation Society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation 2011; 92: 1181-1187.
8. Halme L, Hockerstedt K, Lautenschlager I,. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003; 75: 1853-1858.
9. Hoekstra H, Buis CI, Verdonk RC, van der Hilst CS, van der Jagt EJ, Haagsma EB, Porte RJ,. Is Roux-en-Y choledochojejunostomy an independent risk factor for nonanastomotic biliary strictures after liver transplantation? Liver Transpl 2009; 15: 924-930.
10. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC,. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011; 11: 2181-2189.
11. Pirenne J, Monbaliu D, Aerts R, Desschans B, Liu Q, Cassiman D, et al. Biliary strictures after liver transplantation: risk factors and prevention by donor treatment with epoprostenol. Transplant Proc 2009; 41: 3399-3402.
12. Guichelaar MM, Benson JT, Malinchoc M, Krom RA, Wiesner RH, Charlton MR,. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant 2003; 3: 885-890.
13. Reinhard L, Rupp C, Riedel HD, Ruppert T, Giese T, Flechtenmacher C, et al. S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis. PLoS One 2012; 7: e29821.
14. Korkmaz M, Kunefeci G, Selcuk H, Unal H, Gur G, Yilmaz U, et al. The role of early colonoscopy in CMV colitis of transplant recipients. Transplant Proc 2005; 37: 3059-3060.
15. Jang EY, Park SY, Lee EJ, Song EH, Chong YP, Lee SO, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis 2009; 48: e121-e124.
16. Brantsaeter AB, Holberg-Petersen M, Jeansson S, Goplen AK, Bruun JN,. CMV quantitative PCR in the diagnosis of CMV disease in patients with HIV-infection-a retrospective autopsy based study. BMC Infect Dis 2007; 7: 127.
17. Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ, et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008; 46: 3311-3318.
18. Paraskeva M, Bailey M, Levvey BJ, Griffiths AP, Kotsimbos TC, Williams TP, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11: 2190-2196.
19. Pillet S, Pozzetto B, Jarlot C, Paul S, Roblin X,. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis 2012; 44: 541-548.
20. Lautenschlager I, Halme L, Höckerstedt K, Krogerus L, Taskinen E,. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006; 8: 21-30.
21. Kim JM, Kim SJ, Joh JW, Shin M, Moon JI, Jung GO, et al. The risk factors for cytomegalovirus syndrome and tissue-invasive cytomegalovirus disease in liver transplant recipients who have cytomegalovirus antigenemia. Transplant Proc 2010; 42: 890-894.
22. Paya CV, Hermans PE, Wiesner RH, Ludwig J, Smith TF, Rakela J, Krom RA,. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989; 160: 752-758.
23. Seckert CK, Renzaho A, Tervo HM, Krause C, Deegen P, Kühnapfel B, et al. Liver sinusoidal endothelial cells are a site of murine cytomegalovirus latency and reactivation. J Virol 2009; 83: 8869-8884.
24. Goodrum F, Caviness K, Zagallo P,. Human cytomegalovirus persistence. Cell Microbiol 2012; 14: 644-655.
25. Britt W,. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 2008; 325: 417-470.
26. Cannon MJ, Hyde TB, Schmid DS,. Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. Rev Med Virol 2011; 21: 240-255.
27. Stagno S, Reynolds DW, Pass RF, Alford CA,. Breast milk and the risk of cytomegalovirus infection. N Engl J Med 1980; 302: 1073-1076.
28. Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Häyry PJ, Lemström KB,. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1: 115-126.
29. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100: 61-66.
30. Li YT, Emery VC, Surah S, Jarmulowicz M, Sweny P, Kidd IM, et al. Extensive human cytomegalovirus (HCMV) genomic DNA in the renal tubular epithelium early after renal transplantation: relationship with HCMV DNAemia and long-term graft function. J Med Virol 2010; 82: 85-93.
31. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al.; for Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
32. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652.
33. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461-1464.